Back to Screener

Healthcare

Vasamed, Inc.(VSMD)

Live Price

Offline

$0.0001

+0.00% today

1Y Change

+0.00%

Window

Jun 23, 2025 โ†’ Jun 17, 2026

Market Cap
โ€”
Revenue Growth
+29.7%
EPS Growth
+29.2%
Dividend Yield
0.0%

Coverage: 248 bars ยท Jun 23, 2025 โ†’ Jun 17, 2026

Research Briefing

A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.

Decision context

Research Snapshot

Vasamed, Inc. (VSMD) is a Healthcare stock with listed on OTC. The stock last traded around $0.00 and up 0.0% across the available one-year price window (Jun 23, 2025 โ†’ Jun 17, 2026). Baseline metrics include revenue growth of +29.7%, EPS growth of +29.2%, a dividend yield of 0.0%. What stands out right now is revenue +29.7%, EPS +29.2%, free cash flow -21.5% with operating margin 342.1% and ROIC 742.8%. Valuation is more restrained than many high-expectation growth names at price/sales 0.0. Overall, the current profile looks closer to a quality compounder than a generic broad-market placeholder. Stock Foundry combines VSMD price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.

Sector Context

How this name stacks up against nearby peers on first-pass metrics.

Revenue Growth

Above sector median

+29.7% vs +7.6% peer median

Operating Margin

Above sector median

+342.1% vs +19.4% peer median

What Changed This Quarter

Latest report context and the signals most likely to have changed the story.

Latest report is on the board

2006 was reported on Sep 30, 2006, but the surprise data is still limited.

The operating story is still moving forward

Revenue is running at +29.7% and EPS at +29.2%, with operating margin around 342.1%.

Earnings Reaction Memory

How the stock has tended to move after recent reports.

Across the last 3 reported quarters, the stock averaged 0.0% over the next 5 trading days and finished higher after 0 of those reports.

View quarter-by-quarter reaction table
QuarterEPS ฮ”1D5D20D
2006
Sep 30, 2006
โ€”+0.0%+0.0%+0.0%
2006
Jun 30, 2006
โ€”+0.0%+0.0%+0.0%
2006
Mar 31, 2006
โ€”+0.0%+0.0%+0.0%

Benchmark Comparison

Normalized Performance vs SPY

Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.

1Y shared range

VSMD

โ€”

Normalized return

SPY

โ€”

S&P 500

Excess Return

โ€”

Relative to SPY

VSMD Max Drawdown

0.00%

Trailing 1Y

SPY Max Drawdown

โ€”

Trailing 1Y

Benchmark comparison is loading or unavailable right now.

Calendar-Year Returns

Uses the longest available daily history for VSMD and SPY.

Calendar-year return history is still loading or unavailable.
Vasamed, Inc. logo

Company Overview

Vasamed, Inc.

Other OTC

Eden Prairie, MN, US
Visit vasamed.comCall IR952-944-5857

Vasamed Incorporated designs, licenses, manufactures, and distributes products, software, and services for assessing and managing hemodynamic health in the United States. It offers SensiLase PAD-IQ, which supports skin perfusion pressure, pulse volume recording, and ankle brachial index calculation for Doppler-obtained pressures; and Wound Imaging & SmartDraw wound measurement systems. The company also provides PAD-IQ Studycast that provides rapid transmission of diagnostic tests to vascular specialist for interpretation of results and medically indicated therapeutic intervention; and custom carrying case to secure and protect the PAD-IQ system. It serves clinicians and patients. The company was founded in 1988 and is headquartered in Eden Prairie, Minnesota.

Leadership
Paulita LaPlante
IPO Date
Feb 14, 1996
Street Address
7615 Golden Triangle Drive
Mailing
Eden Prairie, MN, 55344
Region
Eden Prairie, MN, US
Reporting Currency
USD
Investor Line
952-944-5857
Last Updated
May 5, 2026
ISIN: US92834L1026CUSIP: 92834L102
Reports in USD

Key Fundamentals

Valuation, growth, profitability, and balance sheet signals.

Valuation

P/E
โ€”
EV/EBITDA
โ€”
Price/Sales
0.0
Price/Book
0.0

Growth

Revenue
+29.7%
EPS
+29.2%
Free Cash Flow
-21.5%

Profitability

Gross Margin
-5.0%
Operating Margin
342.1%
Net Margin
-352.6%
ROE
315.4%
ROIC
742.8%

Balance Sheet

Debt/Equity
0.04
Current Ratio
0.98

Earnings Reports

๐Ÿ“… Last reportedSep 30, 2006
PeriodB/MEPSEPS ฮ”RevenueRev ฮ”
โ€”
Sep 30, 06
-0.45
Est โ€”
โ€”
513.1B
Est โ€”
โ€”
โ€”
Jun 30, 06
-0.44
Est โ€”
โ€”
463.5B
Est โ€”
โ€”
โ€”
Mar 31, 06
-0.32
Est โ€”
โ€”
456.6B
Est โ€”
โ€”
โ€”
Dec 31, 05
-0.26
Est โ€”
โ€”
572.1B
Est โ€”
โ€”
โ€”
Sep 30, 05
-0.42
Est โ€”
โ€”
344.9B
Est โ€”
โ€”
โ€”
Jun 30, 05
-0.35
Est โ€”
โ€”
195.8B
Est โ€”
โ€”
โ€”
Mar 31, 05
-0.29
Est โ€”
โ€”
273.5B
Est โ€”
โ€”
โ€”
Dec 31, 04
-0.29
Est โ€”
โ€”
365.7B
Est โ€”
โ€”
โ€”
Sep 30, 04
-0.39
Est โ€”
โ€”
284.3B
Est โ€”
โ€”
โ€”
Jun 30, 04
-0.86
Est โ€”
โ€”
234.3B
Est โ€”
โ€”
โ€”
Mar 31, 04
-0.32
Est โ€”
โ€”
184.8B
Est โ€”
โ€”
โ€”
Dec 31, 03
-0.19
Est โ€”
โ€”
411.7B
Est โ€”
โ€”
โ€”
Sep 30, 03
-0.27
Est โ€”
โ€”
560.7B
Est โ€”
โ€”
โ€”
Jun 30, 03
-0.24
Est โ€”
โ€”
262.4B
Est โ€”
โ€”
โ€”
Mar 31, 03
-0.00
Est โ€”
โ€”
889.1B
Est โ€”
โ€”
โ€”
Dec 31, 02
-0.07
Est โ€”
โ€”
974.9B
Est โ€”
โ€”

Latest News

No news articles available

Official Releases

Company announcements and filings-style updates.

Official
No official releases available

Next Step

Keep the research moving

After the overview, the strongest next step is usually chart context or a tighter compare set.

Explore the advanced chart guideRead how to compare stocks